Mitosis is an elaborate process in actively proliferating cells, resulting in the division of duplicated sets of chromosomes and two genetically identical daughter cells. Failure of cell-cycle checkpoint regulations often results in aneuploidy and genetic instability, culminating either in cell death or cancer. Some of the mitotic inhibitors interfere with the normal function of microtubule growth, specifically the beta-subunit of tubulin, by forming a microtubule-drug complex and thereby inhibiting the polymerization of cells, whereas some of the other mitotic inhibitors stabilize the cell function by depolymerizing the microtubules proliferation. Different mitotic inhibitors are used to treat types of cancers such as leukemia, lymphoma, breast cancer, lung cancer, and other types of cancers. Teva Pharmaceuticals, Pfizer, Eisai, Bristol-Myers Squibb, Celgene Corporation, Novartis, and Merck are the key companies that are currently providing mitotic inhibitors for the treatment of cancer patients in the market.
Approved Mitotic Inhibitors
Drugs under the Pipeline for Mitotic Inhibitors
Clinical Activity and Development of Mitotic Inhibitors
There are about 18 approved drug products as mitotic inhibitors in the market and more than 20 products are in the pipeline which are being developed by 29 companies.
The Mitotic inhibitor, Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure and with Doxorubicin and Cyclophosphamide as adjuvant treatment of operable node-positive breast cancer. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer after platinum therapy failure and with Cisplatin for unresectable, locally advanced, or metastatic NSCLC. Docetaxel is indicated with Cisplatin and Fluorouracil for the treatment of metastatic castration-resistant prostate cancer and for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction. Cisplatin and Fluorouracil are also used for induction treatment of locally advanced squamous cell carcinoma of the head and neck in combination with Docetaxel.
Taxotere (Docetaxel), Halaven (Eribulin), Taxol (Paclitaxel) Abraxane (Paclitaxel protein-bound), Vincasar PFS (Vincristine), Vumon (Teniposide) are some of the approved Mitotic Inhibitors.
The global sale of Abraxane for 2022 was US$ 811 million.
Teva Pharmaceuticals, Pfizer, Eisai, Bristol-Myers Squibb, Celgene Corporation, Novartis, and Merck are a few major players in the mitotic inhibitors space.
More than 23,00,000 women are affected by breast cancer globally.